Why Women Are Sicker,
Diagnosed Later,
and Treated Worse

There is a pattern I have seen so many times across thirty-seven years of clinical practice that it has stopped surprising me — though it never stops being worth saying clearly.

A woman in her late thirties or forties. Usually highly functional — working, running a household, holding things together for everyone around her. She has been tired for longer than she can precisely remember. Not the tiredness that sleep fixes. The kind that is there when she wakes up, that accumulates across the week, that requires a level of management and concealment that has itself become exhausting.

She has other symptoms. Maybe her hair is thinning. Maybe her weight has shifted in ways that don't respond to the things that used to work. Maybe her sleep has changed — she falls asleep fine but wakes at three in the morning with a mind that won't stop. Maybe she has a new anxiety that feels qualitatively different from anything she experienced before — less like worry, more like a background hum of physiological dread.

She has been to her GP. Her bloods have come back normal. She may have been told it's stress. She may have been told it's her age. She may have been referred for CBT, or prescribed antidepressants, or both.

She is not depressed. She is biochemically dysregulated in ways that have not been investigated.

The research gap is real and documented

In 1977, the FDA recommended excluding women of childbearing potential from early phase clinical trials. The stated rationale was protecting fetuses from experimental drugs. The practical consequence was four decades of medical research conducted predominantly on male subjects — and the assumption, rarely stated but consistently enacted, that findings in male populations could be extrapolated to female ones.

The NIH Revitalisation Act of 1993 mandated inclusion of women in NIH-funded research. Progress has been real but uneven. A 2020 analysis of cardiovascular clinical trials found women represented only 38% of participants, despite cardiovascular disease being the leading cause of death in women globally. The result is a body of medical knowledge that is less reliable for women than for men across multiple domains — dosing, symptom presentation, diagnostic criteria, and treatment response.

This is not a fringe critique. It is documented in peer-reviewed literature and acknowledged by major health institutions. It has a name: the gender health gap.

Autoimmunity — the most striking disparity

Approximately 80% of autoimmune disease occurs in women. Hashimoto's thyroiditis — the most common cause of hypothyroidism in the developed world — affects women at a ratio of roughly 10:1 over men. Lupus: 9:1. Sjögren's syndrome: 9:1. Rheumatoid arthritis: 3:1. Multiple sclerosis: 3:1.

These are profound and consistent disparities pointing to fundamental sex-based differences in immune regulation — differences that are poorly understood and largely unexplored as a basis for clinical management.

The conventional medical response to an autoimmune diagnosis is typically immunosuppression. This is often necessary. But it does not address why the immune system became dysregulated, and it does nothing for the enormous population of women in the pre-diagnostic phase — who have elevated antibodies, subclinical autoimmune activity, and a constellation of symptoms that don't yet meet diagnostic threshold. Too ill to feel well. Not ill enough, by conventional criteria, to be treated.

Coming back when it gets worse is not a health strategy. It is watchful waiting dressed up as medicine.

The thyroid — where the failure is most visible

The conventional approach to thyroid investigation is TSH. If TSH is within the reference range, the thyroid is fine. This position is difficult to defend clinically.

TSH is a pituitary hormone — a signal, not a direct measure of thyroid function. A woman can have a TSH of 2.8 — completely normal — and simultaneously have free T3 in the bottom quartile of the reference range, elevated TPO antibodies indicating active Hashimoto's autoimmunity, reverse T3 elevated relative to free T3 indicating poor conversion, and a basal body temperature that rarely reaches 37 degrees. None of these will be detected by TSH alone. All of them have clinical consequences.

The frustration of women in this position is entirely rational. They know something is wrong. The investigation they've received is inadequate for the question being asked.

Perimenopause — the decade nobody prepared them for

Perimenopause is the transitional phase preceding menopause. It typically begins in the early to mid-forties and can last anywhere from two to twelve years. During this period, oestrogen doesn't decline smoothly — it fluctuates, sometimes dramatically, before eventually falling. Progesterone tends to decline earlier and more steadily.

The symptoms are consequently not confined to hot flushes and irregular periods. They include sleep disruption (particularly early morning waking), new-onset anxiety, cognitive changes including word-finding difficulties and brain fog, joint pain, palpitations, changes in gut function, skin and hair changes, and altered response to exercise and dietary intervention.

Many of these symptoms present with normal or near-normal hormone levels on a single-point blood test — because the problem is fluctuation and ratio, not necessarily absolute deficiency. The DUTCH Plus — dried urine collected across the day — offers a more complete picture: oestrogen and its metabolites, progesterone, the androgens, cortisol across the diurnal curve, and the downstream metabolites that indicate how hormones are being processed and cleared.

The gut-hormone connection women aren't being told about

There is a community of bacteria in the gut collectively termed the estrobolome — a subset of the microbiome that metabolises oestrogen and influences its recirculation. Certain gut bacteria produce beta-glucuronidase, which deconjugates oestrogen in the gut, allowing it to be reabsorbed into circulation rather than excreted.

When the gut microbiome is dysbiotic, beta-glucuronidase activity can be elevated, contributing to conditions of oestrogen excess or dysregulated oestrogen metabolism: endometriosis, fibroids, oestrogen-dominant PMS, and certain hormonally-driven cancers. The reverse is also true — a depleted microbiome may reduce oestrogen recycling, worsening perimenopausal symptoms.

The connection between gut health and hormonal health is not alternative medicine. It is published science. A woman presenting with hormonal symptoms who receives hormone investigation without gut investigation is receiving an incomplete assessment.

Why fatigue in women is not being taken seriously enough

Women report fatigue at higher rates than men. Women with fatigue are more likely than men to receive a primary psychological explanation. And women are significantly more likely to have fatigue secondary to an underlying physiological cause — thyroid dysfunction, iron deficiency, autoimmune activity, hormonal dysregulation — that is treatable once identified.

The iron story alone is remarkable. Ferritin is typically flagged as normal at levels above 12–15 µg/L. Clinical evidence consistently shows that fatigue, brain fog, hair loss, and poor exercise tolerance persist in many women until ferritin is above 70–80 µg/L. The gap between "not technically iron deficient" and "iron-replete enough to function well" is wide, and women of reproductive age frequently inhabit it.

What functional investigation offers

For a woman in her forties who is fatigued, hormonally disrupted, not sleeping properly, and being told her bloods are fine, the functional investigation I'd typically want to see:

Comprehensive blood chemistry — not just TSH and a full blood count, but ferritin, free T3 and T4, thyroid antibodies, vitamin D, B12, fasting glucose and insulin, full lipid panel with ratios, inflammatory markers, and sex hormones in context.

DUTCH Plus — for a complete picture of hormone production, metabolism, and clearance, including the cortisol and stress hormone picture that sits underneath the sex hormone picture.

GI-MAP — because the gut cannot be separated from the hormonal and immune picture, and because dysbiosis, intestinal permeability, and elevated beta-glucuronidase are often part of what's driving hormonal symptoms.

OAT — for nutritional status, mitochondrial function, oxidative stress burden, and neurotransmitter metabolites that often explain the cognitive and mood components of the presentation.

The women I work with who have had this investigation — many of whom have spent years being told they're fine — consistently describe the experience of seeing their results as a form of validation. Not because the results tell them something is wrong, but because they finally show what is wrong, specifically, in their individual biochemistry.

Related reading